Early Diagnosis

This case study highlights the importance of careful evaluation when determining whether a patient has AL or ATTR cardiac amyloidosis. Read Article ›

At the time of common orthopedic surgeries, amyloid deposition can be detected, especially in patients aged ≥70 years, providing clinicians with an opportunity for early diagnosis. Read Article ›

hATTR risk can be identified through genomic screening and guide management early on, preventing potential diagnostic and treatment delays. Read Article ›

Wild-type transthyretin amyloidosis remains a clinical challenge, exacerbated by diagnostic delays. Read Article ›

Researchers evaluated patient characteristics that may be associated with positive technetium pyrophosphate uptake and aid in the diagnosis of cardiac transthyretin amyloidosis. Read Article ›

Considerable cardiovascular disease burden is often seen in patients with hereditary transthyretin amyloidosis in the 5 years preceding diagnosis. Read Article ›

A complete diagnostic workup is critical to ensure accurate subtyping, with the recognition that both transthyretin and light chain amyloidosis can occur concurrently. Read Article ›

Researchers are developing an algorithm to interpret and manage abnormal monoclonal protein studies in the context of presumed ATTR. Read Article ›

Investigations of subclinical features in hATTR are warranted to understand the potential role of early disease-modifying treatment. Read Article ›

Diagnosis of this disease is often missed and still underdiagnosed, despite recent diagnostic improvements and the use of scintigraphy. Read Article ›

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to recieve: